Ailment Sources and Scientific Publications

Ever since its discovery thousands of years ago, Cannabis has been used as a remedy for a variety of medical ailments. In the past 40 years, there have been hundreds of peer-reviewed journals published that aim to find out what the therapeutic value of Cannabis actually is. There have not, however, been any FDA clinical trials associated with the therapeutic uses of cannabis.Therefore, none of these statements have been evaluated by the FDA. Cannalysis does not make any claims that we or cannabis will diagnose, treat, or cure any medical condition. Individuals should consult a physician before using any medical treatment or product to treat a serious medical condition. We do, however, believe in the scientific method. And so we have gathered just a small sample of some of the work done by researchers to assess the medical benefits of cannabis. Please take some time and educate yourself on this fascinating topic.

Pain Inflammation Muscle Spasms Anxiety Nausea Appetite Siezures Anti-Bacterial Psychosis

Pain Relief (Analgesic)

Cannabis in painful HIV-associated sensory neuropathy A randomized placebo-controlled trial

D. I. Abrams, MD, C. A. Jay, MD, S. B. Shade, MPH, H. Vizoso, RN, H. Reda, BA, S. Press, BS, M. E. Kelly, MPH, M. C. Rowbotham, MD and K. L. Petersen, MD

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial

M. Maurer, V. Henn, A. Dittrich, A. Hofmann

Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial

Ronald J Ellis1, Will Toperoff1, Florin Vaida2, Geoffrey van den Brande3, James Gonzales4, Ben Gouaux5, Heather Bentley5 and J Hampton Atkinson5

Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain

Barth Wilsey, Thomas Marcotte†, Reena Deutsch†, Ben Gouaux†, Staci Sakai‡, Haylee Donaghe‡

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

Mark A. Ware, MBBS, Tongtong Wang, PhD, Stan Shapiro, PhD, Ann Robinson, RN, Thierry Ducruet, MSc, Thao Huynh, MD, Ann Gamsa, PhD, Gary J. Bennett, PhD, Jean-Paul Collet, MD PhD

Inflammation

Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw

Barbara Costa, Mariapia Colleoni, Silvia Conti, Daniela Parolaro, Chiara Franke, Anna Elisa Trovato, Gabriella Giagnoni

Muscle Spasms

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial

M. Maurer, V. Henn, A. Dittrich, A. Hofmann

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

C. Collin1, P. Davies2, I. K. Mutiboko3, S. Ratcliffe

Treatment of Human Spasticity with Δ9-Tetrahydrocannabinol

Denis J. Petro M.D., and Carl Ellenberger Jr. M.D.

Anxiety Relief (Anxiolytic)

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug

Alexandre Rafael de Mello SchierI; Natalia Pinho de Oliveira RibeiroI; Adriana Cardoso de Oliveira e SilvaI,II,IV; Jaime Eduardo Cecílio HallakIII,IV; José Alexandre S. CrippaIII,IV; Antonio E. NardiI,IV; Antonio Waldo ZuardiIII,IV

Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test

Fabrício A. Moreira, Daniele C. Aguiar, Francisco S. Guimarães

Nausea Relief / Appetite Stimulant

Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy

Stephen E. Sallan, M.D., Norman E. Zinberg, M.D., and Emil Frei, III, M.D.

Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy: A Comparison with Prochlorperazine and a Placebo

STEPHEN FRYTAK, M.D.; CHARLES G. MOERTEL, M.D.; JUDITH R. O'FALLON, Ph.D.; JOSEPH RUBIN, M.D.; EDWARD T. CREAGAN, M.D.; MICHAEL J. O'CONNELL, M.D.; ALLAN J. SCHUTT, M.D.; and NEAL W. SCHWARTAU, RPh

Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate: A Prospective, Randomized Evaluation

ALFRED E. CHANG, M.D.; DAVID J. SHILING, M.D.; RICHARD C. STILLMAN, M.D.; NELSON H. GOLDBERG, M.D.; CLAUDIA A. SEIPP, R.N.; IVAN BAROFSKY, Ph.D.; RICHARD M. SIMON, Ph.D.; and STEVEN A. ROSENBERG, M.D., Ph.D.

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

1. Martin R Tramèr (martin.tramer@hcuge.ch), staff anaesthetista, Dawn Carroll, senior research nurseb, Fiona A Campbell, consultant in anaesthetics and pain managementc, John M Reynolds, consultant clinical pharmacologistd, R Andrew Moore, consultant biochemistb, Henry J McQuay, professor of pain relief

Relief from Siezures

Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo

Nicholas A. Jones, Andrew J. Hill, Imogen Smith, Sarah A. Bevan, Claire M. Williams, Benjamin J. Whalley and Gary J. Stephens

Antiepileptic and Prophylactic Effects of Tetrahydrocannabinols in Amygdaloid Kindled Rats

Michael E. Corcoran, James A. McCaughran Jr. and, Juhn A. Wada

Antibacterial

Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw

Barbara Costa, Mariapia Colleoni, Silvia Conti, Daniela Parolaro, Chiara Franke,Anna Elisa Trovato, Gabriella Giagnoni

Calming Effect, Tranquilizing / Relief from Psychosis

Cannabidiol, a Cannabis sativaconstituent, as an antipsychotic drug

A.W. Zuardi2, J.A.S. Crippa2, J.E.C. Hallak2, F.A. Moreira1 and F.S. Guimarães1

A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation

Antonio Waldo Zuardi1 , José Alexandre S. Crippa1,2,*, Jaime E.C. Hallak1 , Sagnik Bhattacharyya2 , Zerrin Atakan2 , Rocio Martín-Santos3 , Philip K. McGuire2 and Francisco Silveira Guimarães4

© 2015-2017. Cannalysis